The TOR pathway: a target for cancer therapy

Nat Rev Cancer. 2004 May;4(5):335-48. doi: 10.1038/nrc1362.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Antibiotics, Antineoplastic / pharmacology
  • Cell Transformation, Neoplastic* / drug effects
  • Humans
  • Phosphatidylinositol 3-Kinases / physiology
  • Protein Kinases / physiology*
  • Protein-Serine-Threonine Kinases / physiology
  • Signal Transduction / physiology*
  • Sirolimus / pharmacology
  • TOR Serine-Threonine Kinases
  • Tacrolimus Binding Proteins / physiology*

Substances

  • Antibiotics, Antineoplastic
  • Protein Kinases
  • Phosphatidylinositol 3-Kinases
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Protein-Serine-Threonine Kinases
  • Tacrolimus Binding Proteins
  • Sirolimus